Recent Updates
Recently added Catalysts
IPSC Positive Sentiment Score: 80/100

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Key Takeaway: Century Therapeutics, a biotechnology company focused on iPSC-derived cell therapies, announced that its CEO, Lalo Flores, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The presentation will highlight the company's innovative approaches in immuno-oncology. Century aims to overcome existing challenges in cancer treatment through its genetically engineered therapies designed for targeting various types of tumors. The event will also include a live webcast, providing broader access to their developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Century Therapeutics is presenting at a major healthcare conference, showcasing their advancements.
  • Their iPSC-derived cell therapies have the potential to overcome limitations of first-generation therapies.
  • The company is committed to developing off-the-shelf therapies, expanding patient access.

Full Press Release Details

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT.
A live webcast of the event will be available on the Events & Presentations page of Century’s website. A replay of the webcast will be archived on the Company's website for a limited time.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit www.centurytx.com.
Century Therapeutics Forward-Looking Statement
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For More Information:
Company: Elizabeth Krutoholow – investor.relations@centurytx.com
Investors: Melissa Forst/Maghan Meyers – century@argotpartners.com
Media: Joshua R. Mansbach – century@argotpartners.com

Frequently Asked Questions

When will Century Therapeutics present at the J.P. Morgan Conference?

Century Therapeutics will present on January 11, 2023, at 9:45 AM PT.

What type of therapies does Century Therapeutics develop?

They develop iPSC-derived cell therapies for cancer in immuno-oncology.

How does Century Therapeutics address cell therapy challenges?

They leverage expertise in cellular reprogramming and genetic engineering.

Where can I find the live webcast of the presentation?

The webcast will be available on the Events & Presentations page of their website.

Last updated: Jan 4, 2023